The global pet allergy treatment market size was valued at USD 2.42 billion in 2025 and is projected to grow from USD 2.55 billion in 2026 to USD 3.93 billion by 2034, registering a CAGR of 5.54% during the forecast period (2026–2034). North America dominated the pet allergy treatment market with a market share of 43.65% in 2025.
Pet allergy treatment includes medicines and therapies used to manage allergic conditions in pets caused by food, fleas, pollen, dust mites, mold, and other environmental allergens. Common treatment options include antihistamines, corticosteroids, immunotherapy, medicated shampoos, prescription diets, and newer biologic therapies that help reduce itching, inflammation, and skin infections. These treatments are widely used for dogs, cats, and other companion animals.
The pet allergy treatment market demand is driven by increasing pet ownership, growing awareness of animal health, and the higher incidence of allergies in companion animals. Better treatment options, improved veterinary care, and ongoing product innovations are also supporting pet allergy treatment market growth.
Download a Free Sample to Explore Detailed Market Insights
The pet allergy treatment market is indirectly exposed to supply chain disruptions, as the availability of pharmaceuticals, biologics, active ingredients, and veterinary consumables depends on global manufacturing and distribution networks. Delays in sourcing raw materials, transportation bottlenecks, and interruptions in cross border trade can affect production schedules, resulting in temporary shortages and longer delivery timelines for veterinary allergy treatments. These challenges increase operational costs for manufacturers and distributors while limiting timely product availability across several regional markets. The market has shown a capacity-constrained recovery, supported by supply chain diversification, regional manufacturing expansion, improved inventory planning, and stronger distribution networks that continue to enhance product availability.
Growing demand for targeted treatments is changing the way pet allergies are managed. Veterinary professionals are gradually moving from repeated symptom-based medications to biologic therapies that provide longer lasting relief with fewer side effects. This shift is improving treatment outcomes for pets with chronic allergic skin conditions while reducing the need for frequent steroid use. For example, Zoetis' Cytopoint is widely used to control itching associated with atopic dermatitis in dogs through targeted immune response management.
Pet owners are increasingly looking for treatment plans based on the specific cause of their pet's allergy rather than using general medications. This has increased the use of allergy testing, elimination diets, and customized nutrition plans alongside medicines to manage recurring allergies more effectively. This approach helps veterinarians provide more accurate treatment and supports long term disease control. For example, Hill's Prescription Diet Derm Complete is formulated to help manage food and environmental allergies in dogs as part of a personalized treatment plan.
The pet allergy treatment market forecasts sustained investments toward advanced biologics, immunotherapies, and precision diagnostics for companion animals. Growing funding for veterinary healthcare infrastructure and animal health innovation is expected to accelerate the development and commercialization of more targeted and long-lasting allergy treatment solutions.
Key Investment and Funding Activities in Pet Allergy Treatment Market, 2026
Vetic
USD 40 Million
In June 2026, Vetic raised a funding round led by Bessemer Venture Partners with participation from Greenoaks Capital, Lachy Groom, and JSW Ventures. The investment will expand veterinary hospitals, diagnostics, specialty care, and treatment capabilities, including management of dermatological and allergic conditions in companion animals.
Aviwell
USD 12.6 Million
In January 2026, Aviwell raised USD 12.6 million to expand its microbiome discovery platform. Although primarily focused on livestock, the investment reflects increasing investor interest in animal immune health and microbiome technologies that have potential applications in companion animal allergy management.
Growing Availability of Veterinary Dermatology Specialists and Increasing Spending on Preventive & Long-term Veterinary Care Drives Market
The expansion of veterinary dermatology practices is improving access to specialized diagnosis and treatment for allergic skin diseases in companion animals. More referral hospitals are offering advanced services such as intradermal allergy testing, serum IgE testing, and allergen-specific immunotherapy, increasing the number of diagnosed cases. This is creating sustained demand for prescription allergy medicines and biologic therapies.
The growing number of pet owners is increasing demand for effective allergy treatments, as more families are willing to spend on preventive and long-term veterinary care. Pets are now treated as family members, leading to higher spending on consultations, prescription medicines, and specialty therapies. This shift is encouraging manufacturers to expand their allergy treatment portfolios and improve product availability.
Limited Availability of Approved Allergy Therapies and Lack of Standardized Diagnostic Tests Restrain Market Expansion
Most advanced allergy medicines are developed and approved for dogs, while treatment options for cats and other companion animals remain comparatively limited. Veterinarians often rely on supportive care and off-label medicines when species-specific products are unavailable. This limits product adoption across a broader companion animal population and slows market expansion.
Environmental allergies in pets cannot be confirmed through a single definitive diagnostic test. Veterinarians often depend on clinical history, exclusion of other skin diseases, and lengthy elimination methods before starting targeted treatment. This delays treatment decisions and reduces the timely use of advanced allergy therapies. As a result, the absence of standardized diagnostic pathways continues to restrain market growth.
Development of Species-Specific Biologic Therapies and Expansion of Direct-to-Consumer Pet Pharmacy Platforms Offer Growth Opportunities to Market Players
Most advanced biologic allergy treatments are currently developed for dogs, leaving a considerable gap in treatment options for cats and other companion animals. This creates opportunities for pharmaceutical companies to develop species-specific monoclonal antibodies and immunomodulatory therapies designed for feline and exotic pet allergies. Expanding research in veterinary immunology and companion animal biologics is expected to support the launch of differentiated products for underserved animal groups. Companies that address this unmet clinical need can strengthen their position in the market.
The rapid growth of licensed online pet pharmacies is making prescription allergy medicines more accessible to pet owners. Digital platforms simplify prescription refills for chronic conditions and improve treatment adherence through home delivery and subscription services. This supports consistent use of allergy therapies and expands the customer base for manufacturers. For example, in 2025, Chewy continued expanding its Autoship and Chewy Pharmacy services, allowing pet owners to receive veterinarian-approved prescription medications through scheduled home deliveries. The continued expansion of regulated veterinary e-pharmacies creates new commercial market opportunities.
Increasing Competition from Low-cost Generics and Difficulty in Demonstrating Clinical Value of New Allergy Therapies Challenges Market Growth
The availability of generic corticosteroids, antihistamines, and topical dermatology products is increasing price competition in veterinary allergy care. Many clinics continue prescribing lower-cost alternatives for mild to moderate allergies, especially in cost-sensitive markets. This limits the uptake of newer biologics and specialty therapies despite their clinical advantages. As a result, manufacturers of premium allergy treatments face greater pressure to demonstrate clear clinical and economic value.
Veterinary clinics increasingly expect evidence that newer allergy therapies provide better long-term outcomes than conventional treatments before adopting them in routine practice. Manufacturers must generate post-market clinical data across different breeds, age groups, and allergy types, which requires considerable time and investment. Limited real-world evidence can slow product acceptance and delay wider adoption of innovative therapies, particularly in value-conscious veterinary practices.
The antihistamines segment accounted for a share of 34.17% in 2025, owing to their use as the first-line treatment for mild allergic conditions, broad availability across veterinary practices, and affordability compared with biologic therapies. Their suitability for seasonal allergies and routine symptom control further supports widespread prescribing.
The immunotherapy segment is expected to grow at a CAGR of around 6.24% during the forecast period, fueled by the increasing use of allergen-specific treatment, rising adoption after confirmatory allergy testing, and its ability to modify the underlying immune response. Growing preference for long-term disease management also supports demand.
In 2025, dogs accounted for a share of 62.07%, as canine atopic dermatitis and flea allergy dermatitis are diagnosed more frequently, dogs receive regular veterinary checkups, and a wider range of approved allergy medicines is available. These factors sustain higher treatment volumes.
The cats segment is expected to grow at a CAGR of 6.38% during the forecast period, fueled by improving recognition of feline allergic skin diseases, increasing indoor cat ownership, and growing veterinary focus on species-specific dermatology care. Better diagnostic practices are supporting earlier treatment initiation.
The veterinary clinics & hospitals accounted for a share of 47.36% in 2025 due to specialist led allergy diagnosis, administration of injectable biologics and immunotherapy, and access to prescription only veterinary medicines. Most chronic allergy cases require clinical monitoring, supporting this channel's leading position.
The retail pharmacies segment is expected to grow at a CAGR of 6.80% during the forecast period, driven by wider availability of maintenance allergy medicines, increasing prescription refill demand, and expansion of licensed veterinary pharmacy networks. Improved access encourages treatment continuity for pets with chronic allergic conditions.
North America: Market Dominance Led by High Companion Animal Healthcare Spending and Advanced Veterinary Dermatology Services
The North America pet allergy treatment market accounted for the largest regional share of 43.65% in 2025, driven by high spending on companion animal healthcare, widespread availability of veterinary dermatology specialists, and strong adoption of prescription allergy therapies. The region also benefits from established pet insurance coverage and broad access to advanced veterinary diagnostics. According to the American Pet Products Association (APPA), 95 million US households owned at least one pet in 2025, including 71 million dog-owning households, reflecting a large companion animal population requiring ongoing veterinary care and allergy management.
The US pet allergy treatment market was valued at USD 920.08 million in 2025, driven by strong acceptance of prescription dermatology products and increasing demand for long-term management of chronic allergic skin diseases. Veterinarians routinely recommend allergy testing, prescription diets, and targeted therapies for recurring cases. According to the American Veterinary Medical Association (AVMA), the US had nearly 127,000 licensed veterinarians in 2025, providing one of the world's largest veterinary care networks and supporting broad access to allergy treatment services.
The pet allergy treatment market in Canada was valued at USD 137.48 million in 2025, supported by strong provincial veterinary healthcare systems, increasing availability of companion animal dermatology referral services, and growing adoption of preventive wellness programs by veterinary clinics. Demand is also benefiting from greater use of prescription therapeutic diets for managing food-related allergies and expanding access to veterinary care in suburban communities.
Asia Pacific: Fastest Growth Driven by Expanding Companion Animal Healthcare Infrastructure and Increasing Demand for Imported Specialty Animal Health Products
The Asia Pacific pet allergy treatment market is expected to grow at a CAGR of 7.21% during the forecast period, showcasing the fastest regional growth. Growth is supported by expanding companion animal healthcare infrastructure, increasing availability of veterinary specialty hospitals, and improving access to prescription dermatology medicines. Growing urban pet ownership and stronger veterinary education are also increasing the diagnosis of allergic skin diseases.
The China pet allergy treatment market size was valued at USD 134.71 million in 2025, supported by rapid growth of urban pet ownership, expansion of premium veterinary hospital chains, and increasing demand for imported specialty animal health products. Pet owners are increasingly seeking advanced care for chronic skin disorders, while veterinary clinics continue to strengthen dermatology services.
The India pet allergy treatment market size was valued at USD 68.91 million in 2025, fueled by the expansion of organized veterinary hospital networks, rising availability of veterinary dermatology consultations in metropolitan cities, and growing demand for premium prescription pet nutrition for allergy management. Increasing awareness among urban pet owners is improving treatment-seeking behavior, while veterinary distributors are expanding access to specialized dermatology products across Tier I and Tier II cities, supporting steady market development.
The Japan pet allergy treatment market was valued at USD 79.50 million in 2025, supported by an aging pet population, increasing demand for long-term management of chronic dermatological conditions, and widespread use of routine preventive veterinary care. Veterinary clinics are placing greater emphasis on early intervention and continuous follow-up for allergic diseases, while high standards of companion animal healthcare encourage the use of advanced prescription therapies and specialized nutritional management.
The pet allergy treatment market competitive landscape is moderately fragmented, with the presence of global animal health companies, specialty veterinary pharmaceutical manufacturers, biotechnology firms, and regional veterinary medicine suppliers. Established players compete through broad product portfolios, strong relationships with veterinary clinics, continuous investment in research, regulatory approvals, and extensive distribution networks. The market ecosystem is driven by developing targeted immunotherapies, innovative dermatology formulations, and products for underserved animal species.
May 2026: Elanco Animal Health commercially launched Befrena (tirnovetmab) in the US following USDA approval.
September 2025: Elanco Animal Health announced that the US FDA approved an updated label for Zenrelia (ilunocitinib tablets), removing previous vaccine-related safety language after review of additional scientific evidence.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanashri Bhapakar is a Senior Research Associate with 3+ years of experience in the Biotechnology sector. She focuses on tracking innovation trends, R&D breakthroughs, and market opportunities within biopharmaceuticals and life sciences. Dhanashri’s deep industry knowledge enables her to provide precise, data-backed insights that help companies innovate and compete effectively in global biotech markets.
We are featured on:
sales@straitsresearch.com